Innovative medicines to extend healthy lifespan.

We extend healthy lifespan through innovative medicines. Our approach centres around developing medicines that target core aging mechanisms to not only treat but prevent age-related diseases.

Pioneering Prevention for A longer healthspan Reduced chronic
disease burden 
A healthier future

Juvenescence is a clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines.

Our approach centres around developing medicines that target core pathways of aging to not only treat but prevent age-related diseases, ensuring that longevity comes with enhanced quality of life. 

By focusing on early disease intervention and prevention, we are committed to transforming how we age, ensuring that added years are healthy and fulfilling.

Multiple Clinical
Medicines from 2024

On track to have five medicines in Phase I or II trials by 2025. These therapies target aging mechanisms, offering early disease intervention.

Innovating across
modalities

Our expert team develops treatments using small molecules, biologics, and cell therapies, focusing on aging’s core pathways to impact various age-related conditions.

Longevity at the core

Our primary goal is prevention, with the notable advantage of potentially increasing lifespan by addressing fundamental aging processes.

OUR TEAM

World-class R&D Leadership

Powered by an unrivaled drug development team, we leverage cutting-edge data science approaches to unlock successful drugs in the aging and longevity space. Our team brings together over 150 years of combined pharmaceutical R&D experience and boasts multiple drug approvals.

Our leadership has an unrivalled track record for delivering value.

IN THE NEWS

Our latest developments